Cited by 6,470Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction ResearchCoronary Interventions and Diagnostics

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation

Open access

The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators·2001·New England Journal of Medicine

DOI 10.1056/nejmoa010746

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Despite current treatments, patients who have acute coronary syndromes without ST-segment elevation have high rates of major vascular events. We evaluated the efficacy and safety of the antiplatelet agent clopidogrel when given with aspirin in such patients. METHODS: We randomly assigned 12,562 patients who had presented within 24 hours after the onset of symptoms to receive clopidogrel (300 mg immediately, followed by 75 mg once daily) (6259 patients) or placebo (6303 patients) in addition to aspirin for 3 to 12 months. RESULTS: The first primary outcome--a composite of death from cardiovascular causes, nonfatal myocardial infarction, or stroke--occurred in 9.3 percent of the patients in the clopidogrel group and 11.4 percent of the patients in the placebo group (relative risk with clopidogrel as compared with placebo, 0.80; 95 percent confidence interval, 0.72 to 0.90; P<0.001). The second primary outcome--the first primary outcome or refractory ischemia--occurred in 16.5 percent of the patients in the clopidogrel group and 18.8 percent of the patients in the placebo group (relative risk, 0.86; 95 percent confidence interval, 0.79 to 0.94; P<0.001). The percentages of patients with in-hospital refractory or severe ischemia, heart failure, and revascularization procedures were also significantly lower with clopidogrel. There were significantly more patients with major bleeding in the clopidogrel group than in the placebo group (3.7 percent vs. 2.7 percent; relative risk, 1.38; P=0.001), but there were not significantly more patients with episodes of life-threatening bleeding (2.2 percent [corrected] vs. 1.8 percent; P=0.13) or hemorrhagic strokes (0.1 percent vs. 0.1 percent). CONCLUSIONS: The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation. However, the risk of major bleeding is increased among patients treated with clopidogrel.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa010746

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Self-citation
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 4,204
Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes
The GUSTO-I Investigators (1998) · New England Journal of Medicine · doi:10.1056/nejm199808133390704 · Cited by 1,431
Self-citation
Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial Infarction
The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators (1998) · New England Journal of Medicine · doi:10.1056/nejm199805213382102 · Cited by 1,330
Self-citation
Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
Rao, A. K., Pratt, C. M., Berke, A. D., Jaffe, A. S., Ockene, I. S., SCHREIBER, T. L., Bell, W. R., Knatterud, G. L., ROBERTSON, T. L., & Terrin, M. L. (1988) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(88)90158-1 · Cited by 979
Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial
Simoons, M. L. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05060-1 · Cited by 698
Low-molecular-weight heparin during instability in coronary artery disease
Fragmin during Instability in Coronary Artery Disease (FRISC) study group (1996) · The Lancet · doi:10.1016/s0140-6736(96)91270-2 · Cited by 683
Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
Wallentin, L. C., Swahn, E., Kontny, F. P., Husted, S., Lagerqvist, B., Ståhle, E., Jd, N., Dellborg, M., Geiran, O. R., Grande, P., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)07350-x · Cited by 405
Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists
Chew, D. P., Bhatt, D. L., Sapp, S. K., & Topol, E. J. (2001) · Circulation · doi:10.1161/01.cir.103.2.201 · Cited by 359

Show all 16 references

Sorted by citations

Items 901–1,000 of 1,007

Effect of Clopidogrel plus ASA vs. ASA Early after TIA and Ischaemic Stroke: A Substudy of the CHARISMA Trial
Hankey, G. J., Johnston, S. C., Easton, J. D., Hacke, W., Mas, J., Brennan, D. M., Mak, K. H., Bhatt, D. L., Fox, K. A. A., Topol, E. J., et al. (2011) · International Journal of Stroke · doi:10.1111/j.1747-4949.2010.00535.x · Cited by 76
Clinical implications of clopidogrel resistance
Miguel, A. D., Ibáñez, B., & Badimón, J. J. (2008) · Thrombosis and Haemostasis · doi:10.1160/th08-01-0049 · Cited by 76
Relation of Proton Pump Inhibitor Use After Percutaneous Coronary Intervention With Drug-Eluting Stents to Outcomes
Gaglia, M. A., Torguson, R., Hanna, N., González, M. A., Collins, S. D., Syed, A. I., Ben‐Dor, I., Maluenda, G., Delhaye, C., Wakabayashi, K., et al. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.10.063 · Cited by 76
Outcome of percutaneous coronary intervention versus coronary bypass grafting for patients with low left ventricular ejection fractions, unstable angina pectoris, and risk factors for adverse outcomes with bypass (the AWESOME Randomized Trial and Registry)
Sedlis, S. P., Ramanathan, K. B., Morrison, D. A., Sethi, G. K., Sacks, J. M., & Henderson, W. G. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.03.041 · Cited by 76
Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions
Hosokawa, K., Ohnishi, T., Sameshima, H., Miura, N., Ito, T., Koide, T., & Maruyama, I. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-06-0441 · Cited by 76
Total First-Year Costs of Acute Coronary Syndrome in a Managed Care Setting
Etemad, L. R., & McCollam, P. L. (2005) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2005.11.4.300 · Cited by 76
Part 5: Acute coronary syndromes
Nikolaou, N. I., Welsford, M., Beygui, F., Bossaert, L. L., Ghaemmaghami, C. A., Nonogi, H., O’Connor, R. E., Pichel, D. R., Scott, T., Walters, D., et al. (2015) · Resuscitation · doi:10.1016/j.resuscitation.2015.07.043 · Cited by 78
Novel Antiplatelet Therapies for Atherothrombotic Diseases
Majithia, A., & Bhatt, D. L. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310955 · Cited by 81
Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis
Conley, P. B., & Delaney, S. M. (2003) · Current Opinion in Hematology · doi:10.1097/00062752-200309000-00002 · Cited by 76
Dual Antiplatelet Therapy Prior to Expedited Carotid Surgery Reduces Recurrent Events Prior to Surgery without Significantly Increasing Peri-operative Bleeding Complications
Batchelder, A. J., Hunter, J., Cairns, V., Sandford, R. M., Munshi, A., & Naylor, A. R. (2015) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2015.07.019 · Cited by 75
High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention and Effects on Platelet Inhibition, Endothelial Function, and Inflammation
Patti, G., Grieco, D., Dicuonzo, G., Pasceri, V., Nusca, A., & Sciascio, G. D. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.050 · Cited by 75
Perioperative use of anti-platelet drugs
Chassot, P., Delabays, A., & Spahn, D. R. (2007) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2007.02.002 · Cited by 75
Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry
Ruff, C. T., Bhatt, D. L., Steg, P. G., Gersh, B. J., Alberts, M. J., Hoffman, E. B., Ohman, E. M., Eagle, K. A., Lip, G. Y. H., & Goto, S. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.11.030 · Cited by 74
Incidence, Predictors, and Prognostic Implications of Hospitalization for Late Bleeding After Percutaneous Coronary Intervention for Patients Older Than 65 Years
Ko, D. T., Yun, L., Wijeysundera, H. C., Jackevicius, C. A., Rao, S. V., Austin, P. C., Marquis, J.-F., & Tu, J. V. (2010) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.109.928721 · Cited by 75
Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor
Hansson, E. C., Hakimi, C. S., Åström-Olsson, K., Hesse, C., Wallén, H., Dellborg, M., Albertsson, P., & Jeppsson, A. (2013) · British Journal of Anaesthesia · doi:10.1093/bja/aet339 · Cited by 76
Modern Management of Acute Myocardial Infarction
Yang, E. H., Brilakis, E. S., Reeder, G. S., & Gersh, B. J. (2006) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2006.08.004 · Cited by 76
Gender differences in cardiovascular prophylaxis: Focus on antiplatelet treatment
Giosia, P. D., Passacquale, G., Petrarca, M., Giorgini, P., Marra, A. M., & Ferro, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.025 · Cited by 78
Relationship Between Intermittent Claudication, Inflammation, Thrombosis, and Recurrent Cardiac Events Among Survivors of Myocardial Infarction
Narins, C. R. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.4.440 · Cited by 75
Sequential proteome alterations during genesis and progression of colon cancer
Gustafsson, M., Bruch, H.-P., Franz�n, B., Ried, T., Bergmann, T., Auer, G., J�rnvall, H., Roblick, U. J., Hirschberg, D., Habermann, J. K., et al. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4049-4 · Cited by 75
The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and “Asian Paradox”
Kang, J., & Kim, H.-S. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2018.0166 · Cited by 74
Blood cells: an historical account of the roles of purinergic signalling
Burnstock, G. (2015) · Purinergic Signalling · doi:10.1007/s11302-015-9462-7 · Cited by 74
Atherothrombosis: Epidemiology, Pathophysiology, and Prevention
Munger, M. A., & Hawkins, D. (2004) · Journal of the American Pharmacists Association · doi:10.1331/154434504322904569 · Cited by 74
Clopidogrel resistance: The way forward
Ray, S. (2014) · Indian Heart Journal · doi:10.1016/j.ihj.2014.08.012 · Cited by 74
Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non—Q-wave myocardial infarction
Jacobsson, F., Swahn, E., Wallentin, L. C., & Dellborg, M. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)85149-9 · Cited by 74
Antiplatelet Treatment for Prevention of Cerebrovascular Events in Patients With Vascular Diseases
Gouya, G., Arrich, J., Wolzt, M., Huber, K., Verheugt, F. W. A., Gurbel, P. A., Pirker-Kees, A., & Siller-Matula, J. M. (2013) · Stroke · doi:10.1161/strokeaha.113.002590 · Cited by 73
Relation of Characteristics of Metabolic Syndrome to Short-Term Prognosis and Effects of Intensive Statin Therapy After Acute Coronary Syndrome
Schwartz, G. G., OLSSON, A. G., Szarek, M. J., & Sasiela, W. J. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2508 · Cited by 72
Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy
Smith, S., Judge, H. M., Peters, G. R., Armstrong, M., Fontana, P., Gaussem, P., Daly, M. E., & Storey, R. F. (2006) · Platelets · doi:10.1080/09537100500475844 · Cited by 74
Dual antiplatelet therapy for secondary prevention of coronary artery disease
Degrauwe, S., Pilgrim, T., Aminian, A., Noble, S., Meier, P., & Iglesias, J. F. (2017) · Open Heart · doi:10.1136/openhrt-2017-000651 · Cited by 75
Influence of clinical trial enrollment on the quality of care and outcomes for patients with non–ST-segment elevation acute coronary syndromes
Kandzari, D. E., Roe, M. T., Chen, A. Y., Lytle, B. L., Pollack, C. V., Harrington, R. A., Ohman, E. M., Gibler, W. B., & Peterson, E. D. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.11.014 · Cited by 74
Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified
Serebruany, V. (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-12-0807 · Cited by 73
Meta-Analysis of Randomized Clinical Trials Comparing Short-Term Versus Long-Term Dual Antiplatelet Therapy Following Drug-Eluting Stents
El‐Hayek, G. E., Messerli, F. H., Bangalore, S., Hong, M. K., Herzog, E., Benjo, A. M., & Tamis‐Holland, J. E. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.04.035 · Cited by 73
Non–ST-Segment Acute Coronary Syndromes
Hedayati, T., Yadav, N., & Khanagavi, J. (2017) · Cardiology Clinics · doi:10.1016/j.ccl.2017.08.003 · Cited by 79
The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD)
Akkaif, M. A., Daud, N. A. A., Sha’aban, A., Ng, M. L., Kader, M. A. S. A., Noor, D. A. M., & Ibrahim, B. (2021) · Molecules · doi:10.3390/molecules26071987 · Cited by 73
Effect of Prasugrel Pre-Treatment Strategy in Patients Undergoing Percutaneous Coronary Intervention for NSTEMI
Montalescot, G., Collet, J., Ecollan, P., Bolognese, L., ten Berg, J. M., Dudek, D., Hamm, C. W., Widimský, P., Tanguay, J., Goldstein, P., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.08.053 · Cited by 73
The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis
Pamukçu, B., Oflaz, H., & Nişancí, Y. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.10.007 · Cited by 73
A prospective control study of the safety and cellular yield of EUS-guided FNA or Trucut biopsy in patients taking aspirin, nonsteroidal anti-inflammatory drugs, or prophylactic low molecular weight heparin
Vu, C. K.-F., Chang, F., Doig, L. A., & Meenan, J. K. (2006) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2005.09.033 · Cited by 73
Pharmacodynamic and pharmacokinetic evaluation of clopidogrel and the carboxylic acid metabolite SR 26334 in healthy dogs
Brainard, B. M., Kleine, S. A., Papich, M. G., & Budsberg, S. C. (2010) · American Journal of Veterinary Research · doi:10.2460/ajvr.71.7.822 · Cited by 73
Benefits From New ADP Antagonists as Compared With Clopidogrel in Patients With Stable Angina or Acute Coronary Syndrome Undergoing Invasive Management
Verdoia, M., Schaffer, A., Barbieri, L., Cassetti, E., Piccolo, R., Galasso, G., Marino, P. N., Sinigaglia, F., & Luca, G. D. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000052 · Cited by 73
Resistance to antiplatelet drugs: current status and future research
Tantry, U. S., Bliden, K. P., & Gurbel, P. A. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.12.2027 · Cited by 72
Application of Current Guidelines to the Management of Unstable Angina and Non-ST-Elevation Myocardial Infarction
D, E. B. M. (2003) · Circulation · doi:10.1161/01.cir.0000086952.14979.32 · Cited by 73
Antiplatelet agents for chronic kidney disease
Palmer, S. C., Micco, L. D., Razavian, M., Craig, J. C., Perkovic, V., Pellegrini, F., Jardine, M., Webster, A. C., Zoungas, S., & Strippoli, G. F. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008834.pub2 · Cited by 73
JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease
Nakamura, M., Yaku, H., Ako, J., Arai, H., Asai, T., Chikamori, T., Daida, H., Doi, K., Fukui, T., Ito, T., et al. (2022) · Institutional Repositories DataBase (IRDB) · doi:10.1253/circj.cj-20-1282 · Cited by 70
Platelet Adenosine Diphosphate P2Y12 Receptor Antagonism: Benefits and Limitations of Current Treatment Strategies and Future Directions
Angiolillo, D. J., & Ferreiro, J. L. (2010) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(10)70010-4 · Cited by 75
Colonic diverticular hemorrhage associated with the use of nonsteroidal anti‐inflammatory drugs, low‐dose aspirin, antiplatelet drugs, and dual therapy
Nagata, N., Niikura, R., Aoki, T., Shimbo, T., Kishida, Y., Sekine, K., Tanaka, S., Watanabe, K., Sakurai, T., Yokoi, C., et al. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12595 · Cited by 72
Management of Antiplatelet and Anticoagulant Therapy in Patients With Atrial Fibrillation in the Setting of Acute Coronary Syndromes or Percutaneous Coronary Interventions
Capodanno, D., & Angiolillo, D. J. (2014) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.113.001150 · Cited by 73
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors Task Force Members, Rydén, L., Standl, E., Bartnik, M., den Berghe, G. V., Betteridge, J. D., de Boer, M., Cosentino, F., Jönsson, B., Laakso, M., et al. (2007) · European Heart Journal Supplements · doi:10.1093/eurheartj/ehl261 · Cited by 76
Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischaemic Attack or Ischaemic Stroke (MATCH): Study Design and Baseline Data
Diener, H., Bogousslavsky, J., Brass, L. M., Cimminiello, C., Csiba, L., Kaste, M., Leys, D., Matías‐Guiu, J. A., & Rupprecht, H. (2003) · Cerebrovascular Diseases · doi:10.1159/000076962 · Cited by 72
Pharmacologic therapy for peripheral arterial disease and claudication
Hiatt, W. R. (2002) · Journal of Vascular Surgery · doi:10.1067/mva.2002.129654 · Cited by 71
New Directions in Antiplatelet Therapy
Ferreiro, J. L., & Angiolillo, D. J. (2012) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.111.966176 · Cited by 72
Visualization of Activated Platelets by Targeted Magnetic Resonance Imaging Utilizing Conformation-Specific Antibodies against Glycoprotein IIb/IIIa
Mühlen, C. V. Z., Peter, K., Ali, Z. A., Schneider, J. E., McAteer, M. A., Neubauer, S., Channon, K. M., Bode, C., & Choudhury, R. P. (2008) · Journal of Vascular Research · doi:10.1159/000135660 · Cited by 71
Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO)
Abrignani, M. G., Gatta, L., Gabrielli, D., Milazzo, G., Francesco, V. D., Luca, L. D., Francese, M., Imazio, M., Riccio, E., Rossini, R., et al. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.11.014 · Cited by 78
A Comparative Study of Dual versus Monoantiplatelet Therapy in Patients with Acute Large-Artery Atherosclerosis Stroke
Yi, X., Lin, J., Wang, C., Zhang, B., & Chi, W. (2014) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2014.01.022 · Cited by 71
Platelet Extracellular Regulated Protein Kinase 5 Is a Redox Switch and Triggers Maladaptive Platelet Responses and Myocardial Infarct Expansion
Cameron, S. J., Ture, S. K., Mickelsen, D. M., Chakrabarti, E., Modjeski, K. L., McNitt, S. A., Seaberry, M., Field, D. J., Le, N., Abe, J., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.015656 · Cited by 71
Unidades de dolor torácico. Organización y protocolo para el diagnóstico de los síndromes coronarios agudos
Fernández, J. B., Ezquerra, E. A., Bosch, X., O’Callaghan, A. C., Iglesias-Gárriz, I., Nácher, J. J. J., de Torres, F. M., & Romero, G. S. (2002) · Revista Española de Cardiología · doi:10.1016/s0300-8932(02)76574-3 · Cited by 71
Short‐term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention
Porter, A., Konstantino, Y., Iakobishvili, Z., Shachar, L., Battler, A., & Hasdai, D. (2006) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.20733 · Cited by 71
Platelet glycoprotein IIb/IIIa antagonists: Lessons learned from clinical trials and future directions
Leclerc, J. R. (2002) · Critical Care Medicine · doi:10.1097/00003246-200205001-00025 · Cited by 71
A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction
Gluckman, T. J., Baranowski, B. J., Ashen, M. D., Henrikson, C. A., McAllister, M. W., Braunstein, J. B., & Blumenthal, R. S. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.14.1490 · Cited by 69
Pharmacological therapy for the prevention of cardiovascular events in patients with myocardial infarction with non-obstructed coronary arteries (MINOCA): Insights from a multicentre national registry
Ciliberti, G., Verdoia, M., Merlo, M., Zilio, F., Vatrano, M., Bianco, F., Mancone, M., Zaffalon, D., Bonci, A., Boscutti, A., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.11.040 · Cited by 70
STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management
Tibi, P. R., McClure, R. S., Huang, J., Baker, R. A., Fitzgerald, D., Mazer, C. D., Stone, M. E., Chu, D., Stammers, A. H., Dickinson, T., et al. (2021) · Journal of ExtraCorporeal Technology · doi:10.1051/ject/202153097 · Cited by 115
Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses
Storey, R. F., Bliden, K. P., Ecob, R., Karunakaran, A., Butler, K. A., Wei, C., Tantry, U. S., & Gurbel, P. A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04419.x · Cited by 70
Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost‐effectiveness analysis
Lala, A., Berger, J. S., Sharma, G. K., Hochman, J. S., Braithwaite, R. S., & Ladapo, J. A. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12059 · Cited by 72
Cardiovascular disease and chronic kidney disease: Insights and an update
Best, P. J. M., Reddan, D. N., Berger, P. B., Szczech, L. A. M., McCullough, P. A., & Califf, R. M. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.04.011 · Cited by 71
Cangrelor: a review on pharmacology and clinical trial development
Franchi, F., Rollini, F., Muñiz‐Lozano, A., Cho, J. R., & Angiolillo, D. J. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2013.837701 · Cited by 74
Low-dose aspirin-induced gastrointestinal diseases: past, present, and future
Shiotani, A., Kamada, T., & Haruma, K. (2008) · Journal of Gastroenterology · doi:10.1007/s00535-008-2206-5 · Cited by 70
Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues
Ross, S. A., Anand, S. S., Joseph, P. G., & Paré, G. (2012) · JRSM Cardiovascular Disease · doi:10.1258/cvd.2012.012001 · Cited by 72
Apelin: an antithrombotic factor that inhibits platelet function
Adam, F., Khatib, A., López, J. J., Vatier, C., Turpin, S., Muscat, A., Soulet, F., Aries, A., Jardín, I., Bobe, R., et al. (2015) · Blood · doi:10.1182/blood-2014-05-578781 · Cited by 71
Eicosanoids in platelets and the effect of their modulation by aspirin in the cardiovascular system (and beyond)
Crescente, M., Menke, L., Chan, M. V., Armstrong, P. C. J., & Warner, T. D. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14196 · Cited by 78
Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Treated With Glycoprotein IIb/IIIa Inhibitors or Thienopyridines
Jolly, S. S., Faxon, D. P., Fox, K. A. A., Afzal, R., Boden, W. E., Widimský, P., Steg, P. G., Valentín, V., Budaj, A., Granger, C. B., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.03.062 · Cited by 70
In Vivo Blockade of Platelet ADP Receptor P2Y 12 Reduces Embolus and Thrombus Formation but Not Thrombus Stability
van Gestel, M. A., Heemskerk, J. W. M., Slaaf, D. W., Heijnen, V. V. T., Reneman, R. S., & Egbrink, M. G. A. O. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000057809.32354.22 · Cited by 70
Implementation of Medicare Part D and Nondrug Medical Spending for Elderly Adults With Limited Prior Drug Coverage
McWilliams, J. M., Zaslavsky, A. M., & Huskamp, H. A. (2011) · JAMA · doi:10.1001/jama.2011.1026 · Cited by 69
Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases
Jourdi, G., Lordkipanidzé, M., Philippe, A., Bachelot‐Loza, C., & Gaussem, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313079 · Cited by 76
Timing, Selection, Modulation, and Duration of P2Y12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing PCI
Capodanno, D., & Angiolillo, D. J. (2023) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2022.10.023 · Cited by 70
Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The Global Registry of Acute Coronary Events
Fox, K. A. A., Carruthers, K. F., Steg, P. G., Avezum, Á., Granger, C. B., Montalescot, G., Goodman, S. G., Gore, J. M., Quill, A. L., Eagle, K. A., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp499 · Cited by 69
Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model
Zhou, X., Huang, Y., Khalil, M. K., Wiktor, D. M., van Giezen, J. J. J., Penn, M. S., & Wang, K. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-12-0823 · Cited by 69
Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug‐eluting stent thrombosis
Slottow, T. L. P., & Waksman, R. (2007) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.21179 · Cited by 69
Upper Gastrointestinal Bleeding in Patients with Aspirin and Clopidogrel Co-Therapy
Ng, F., Lam, K., Wong, S., Chang, C.-M., Lau, Y., Yuen, W., Chu, W., & Yu, W. B. C. (2008) · Digestion · doi:10.1159/000141264 · Cited by 69
Cytochrome P450 Gene Variants, Race, and Mortality Among Clopidogrel-Treated Patients After Acute Myocardial Infarction
Cresci, S., Depta, J. P., Lenzini, P. A., Li, A. Y., Lanfear, D. E., Province, M. A., Spertus, J. A., & Bach, R. G. (2014) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.113.000303 · Cited by 69
Improved adherence to Swedish national guidelines for acute myocardial infarction: The Quality Improvement in Coronary Care (QUICC) study
Carlhed, R., Bojestig, M., Wallentin, L. C., Lindström, G., Peterson, A., Åberg, C., & Lindahl, B. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.07.028 · Cited by 69
Association of platelet responsiveness with clopidogrel metabolism: Role of compliance in the assessment of “resistance”
Serebruany, V. L., Cherala, G., Williams, C. D., Surigin, S., Booze, C., Kuliczkowski, W., & Atar, D. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.10.012 · Cited by 71
Safety of Preoperative Use of Ticagrelor With or Without Aspirin Compared With Aspirin Alone in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Grafting
Gherli, R., Mariscalco, G., Dalén, M., Onorati, F., Perrotti, A., Chocron, S., Verhoye, J., Gulbins, H., Reichart, D., Svenarud, P. K., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.3028 · Cited by 69
Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: Further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study
Lewis, B. S., Mehta, S. R., Fox, K. A. A., Halon, D. A., Zhao, F., Peters, R. J. G., Keltai, M., Budaj, A., & Yusuf, S. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.01.044 · Cited by 69
Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention
Broussalis, E., Killer‐Oberpfalzer, M., McCoy, M. R., Harrer, A., Trinka, E., & Kraus, J. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.11.005 · Cited by 71
Inhibición del receptor plaquetario P2Y12 de adenosina difosfato plaquetario: efectos beneficiosos y limitaciones de las estrategias terapéuticas actuales y perspectivas futuras
Angiolillo, D. J., & Ferreiro, J. L. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70010-5 · Cited by 68
Pretreatment With Antiplatelet Drugs in Invasively Managed Patients With Coronary Artery Disease in the Contemporary Era
Capodanno, D., & Angiolillo, D. J. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.002301 · Cited by 68
From Early Pharmacology to Recent Pharmacology Interventions in Acute Coronary Syndromes
Szummer, K. E., Jernberg, T., & Wallentin, L. C. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.531 · Cited by 70
Enfermedad cardiovascular en el anciano
Jackson, C. F., & WENGER, N. K. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.05.001 · Cited by 72
Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus
Angiolillo, D. J., & Suryadevara, S. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.12.001 · Cited by 68
Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations inP2RY12, P2RY1,andITGB3
Storey, R. F., Thornton, S., Lawrance, R. M., Husted, S., Wickens, M., Emanuelsson, H., Cannon, C. P., Heptinstall, S., & Armstrong, M. (2009) · Platelets · doi:10.1080/09537100903075324 · Cited by 68
Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention
Newsome, L. T., Kutcher, M. A., & Royster, R. L. (2008) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181732049 · Cited by 68
Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes
Eikelboom, J. W. (2002) · European Heart Journal · doi:10.1053/euhj.2000.3234 · Cited by 68
Assessment of Dual-Antiplatelet Regimen for Pipeline Embolization Device Placement: A Survey of Major Academic Neurovascular Centers in the United States
Gupta, R., Moore, J. M., Griessenauer, C. J., Adeeb, N., Patel, A. S., Youn, R., Poliskey, K., Thomas, A. J., & Ogilvy, C. S. (2016) · World Neurosurgery · doi:10.1016/j.wneu.2016.09.013 · Cited by 68
A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation
Kamath, S., Blann, A. D., Chin, B., & Lip, G. Y. H. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01984-8 · Cited by 68
Outcome of Myocardial Infarction in Patients Treated with Aspirin Is Enhanced by Pre-Hospital Administration
Barbash, I. M., Freimark, D., Gottlieb, S., Hod, H., Hasin, Y., Battler, A., Crystal, E., Matetzky, S., Boyko, V., Mandelzweig, L., et al. (2002) · Cardiology · doi:10.1159/000066324 · Cited by 104
Relation of Low Response to Clopidogrel Assessed With Point-of-Care Assay to Periprocedural Myonecrosis in Patients Undergoing Elective Coronary Stenting for Stable Angina Pectoris
Cuisset, T., Hamilos, M. I., Sarma, J., Sarno, G., Wyffels, E., Vanderheyden, M., Barbato, E., Bartúnek, J., Bruyne, B. D., & Wijns, W. C. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.054 · Cited by 67
Diabetes and the platelet: Toward new therapeutic paradigms for diabetic atherothrombosis
Morel, O., Kessler, L., Ohlmann, P., & Bareiss, P. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.03.019 · Cited by 67
Dinucleoside polyphosphates: strong endogenous agonists of the purinergic system
Jankowski, V., van der Giet, M., Mischak, H., Morgan, M., Zidek, W., & Jankowski, J. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00337.x · Cited by 67
Effect of CYP2C19*2 and *17 Genetic Variants on Platelet Response to Clopidogrel and Prasugrel Maintenance Dose and Relation to Bleeding Complications
Grosdidier, C., Quilici, J., Loosveld, M., Camoin‐Jau, L., Moro, P.-J., Saut, N., Gaborit, B., Pankert, M., Cohen, W., Lambert, M., et al. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.12.013 · Cited by 66
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
Effect of Addition of Clopidogrel to Aspirin on Mortality: Systematic Review of Randomized Trials
Palacio, S., Hart, R. G., Pearce, L. A., & Benavente, O. R. (2012) · Stroke · doi:10.1161/strokeaha.112.656173 · Cited by 47
Global mapping of randomised trials related articles published in high-impact-factor medical journals: a cross-sectional analysis
Catalá-López, F., Aleixandre-Benavent, R., Caulley, L., Hutton, B., Tabarés-Seisdedos, R., Moher, D., & Alonso-Arroyo, A. (2020) · Trials · doi:10.1186/s13063-019-3944-9 · Cited by 38

Authors: The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Affiliations: Hamilton General Hospital (CA)
Corresponding author: The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2001-08-16
Volume: 345
Issue: 7
Pages: 494-502
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa010746
OpenAlex: W1553345686
Cited by: 6,470
References: 16
Citations by year: 2026: 63 · 2025: 99 · 2024: 77 · 2023: 110 · 2022: 121 · 2021: 163 · 2020: 168 · 2019: 202 · 2018: 216 · 2017: 229 · 2016: 265 · 2015: 325 · 2014: 319 · 2013: 397 · 2012: 395
FWCI: 178.22
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Keywords: clopidogrel, aspirin, antiplatelet therapy, major bleeding, refractory ischemia, cardiovascular mortality, myocardial infarction, stroke, heart failure, revascularization
MeSH terms: Clopidogrel, Acute Disease, Aged, Aspirin, Cardiovascular Diseases, Drug Therapy, Combination, Electrocardiography, Female, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Risk Factors, Ticlopidine, Myocardial Ischemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks